Kamada Ltd. filings document a foreign private issuer reporting on a global biopharmaceutical business focused on specialty plasma-derived therapies and marketed products for rare and serious conditions. Recent Form 6-K reports include exhibits on financial results, annual guidance, investor presentations, product-supply tenders, and FDA approval of a plasma collection center.
The filings also record ordinary-share dividend actions, withholding-tax procedures tied to Israeli tax rules, and incorporation of certain current reports by reference into Form S-8 registration statements. Kamada files as a Form 20-F issuer, with disclosures covering governance, capital-return actions, commercial portfolio performance and regulatory events affecting plasma collection and product supply.
Kamada Ltd. director Payorski Lilach reported administrative option changes involving employee stock options held by a trustee under the company’s 2011 Share Award Plan. The filing shows four grant/award acquisitions and four dispositions to the issuer, each for 7,500 options over Ordinary Shares.
The options carry exercise prices of $5.87 or $6.12 per share and expire on June 22, 2029. Footnotes state the exercise prices were adjusted under the plan following a cash dividend declared on March 11, 2026, and that all U.S. dollar exercise prices reflect a conversion from NIS. The options vest in four equal annual installments, with 25% vesting on each anniversary of the grant date.
Kamada Ltd. obtained a tax ruling from the Israel Tax Authority covering Israeli withholding tax on its previously announced cash dividend of $0.25 (approximately NIS 0.77) per share, totaling about $14.4 million.
Nazdaq shareholders who were on record as of March 23, 2026 and reside in tax treaty countries may qualify for a Reduced Withholding Tax Rate, and certain Israeli corporate holders may qualify for an exemption, if they follow the ruling’s procedures.
Kamada appointed IBI Trust Management as tax processing agent, and eligible Nasdaq shareholders must submit all required documentation by May 9, 2026 to benefit. The dividend is expected to be paid on April 7, 2026 and is not an indication of future dividends.
Kamada Ltd. reports that the U.S. FDA has approved its plasma collection center in San Antonio, Texas, following a February 2026 on-site inspection. The facility can support up to 50 donor beds and has a planned annual collection capacity of approximately 50,000 liters of normal source plasma at full capacity.
The San Antonio center is expected to generate annual revenues of $8 million to $10 million at full capacity and is anticipated to be one of the largest specialty plasma collection centers in the U.S. Together with existing sites in Houston and Beaumont, Kamada now operates three FDA-approved plasma centers in Texas and plans to seek European Medicines Agency approval for the San Antonio site.
Kamada Ltd director and 10% owner Davidi Ishay has filed an initial Form 3 detailing his ownership in the company. The filing reports indirect ownership of 22,084,287 Ordinary Shares held through controlled entities. It also lists several option grants over Ordinary Shares with exercise prices of 7.5200 and 6.1500 per share, expiring on September 25, 2026 and June 22, 2029. Each option grant covers either 6,625 or 7,500 underlying Ordinary Shares and is exercisable using a net-exercise method, with exercise prices translated from NIS to U.S. dollars based on a Bank of Israel exchange rate.
Kamada Ltd. reports a minor adjustment to its upcoming cash dividend schedule. The company previously declared a cash dividend of $0.25 per ordinary share, or approximately NIS 0.77 per share, totaling about $14.4 million, under its newly adopted annual cash dividend policy.
The dividend will now be paid on April 7, 2026, instead of April 6, 2026, to shareholders of record at the close of business on March 23, 2026. All other terms of the dividend, including amount and record date, remain unchanged. Kamada also reiterates forward-looking statements about its intention to pay annual cash dividends of at least 50% of its annual net income, subject to various business, financial, and regulatory risks.
KAMADA LTD director Lilach Payorski has filed an initial Form 3 disclosing option holdings in the company. The filing reports four grants of options to purchase 7,500 ordinary shares each, covering a total of 30,000 shares at an exercise price of $6.15 per share.
The options are exercisable using a net-exercise method and all expire on June 22, 2029. The tranches become exercisable on December 22, 2023, December 22, 2024, December 22, 2025 and December 22, 2026, respectively. Exercise prices are presented in U.S. dollars based on the Bank of Israel exchange rate as of March 13, 2026.
Kamada Ltd. director Assaf Itshayek filed a Form 3 reporting existing holdings of stock options for Ordinary Shares. The filing lists four option positions, each covering 4,000 underlying Ordinary Shares at an exercise price of $6.26 per share, expiring on March 7, 2030, with different future exercise dates from September 7, 2024 through September 7, 2027. The options are exercisable using a net-exercise method, and the U.S. dollar exercise prices reflect a convenience translation from New Israeli Shekels based on the Bank of Israel exchange rate as of March 13, 2026.
KAMADA LTD filed an amended Schedule 13G/A reporting beneficial ownership positions as of 12/31/2025. The filing shows Gov Financial Holdings Ltd. holds 1,455,458 ordinary shares (2.52%), Insight Capital Ltd. holds 1,346,334 shares (2.33%), and Leon Recanati beneficially owns 3,481,937 shares (6.04%).
The summary states Mr. Recanati directly holds 631,145 shares and options exercisable for 49,000 shares within 60 days of 12/31/2025. The filing uses 57,686,056 ordinary shares as the base for percentage calculations. The amendment is signed by Mr. Recanati on 03/16/2026.
Kamada Ltd executive Boris Gorelik filed an initial statement of beneficial ownership, reporting stock option holdings rather than new trades. The filing lists several grants of options to purchase Ordinary Shares, including tranches for 3,750 underlying shares at an exercise price of $9.4300 per share expiring on February 11, 2027, and 15,000 underlying shares at $5.0400 per share expiring on January 16, 2029. Additional option grants cover 15,000 underlying shares at an exercise price of $7.1400 per share expiring on October 22, 2035. The options are exercisable using a net-exercise method, and all exercise prices shown in the filing are convenience translations from New Israeli Shekels into U.S. dollars based on the Bank of Israel’s representative exchange rate as of March 13, 2026.
Kamada Ltd Chief Executive Officer Amir London reported his equity holdings in the company. He directly owns 61,875 Ordinary Shares and also holds several grants of options to purchase Ordinary Shares, each covering 100,000 underlying shares at exercise prices of $6.15 and $7.55 per share, with expirations in 2029 and 2035. The options are exercisable using a net-exercise method, meaning only the in-the-money value is settled in shares rather than paying cash for the full exercise price.